Collagenofibrotic glomerulopathy—a review

Rajan Duggal¹, Ritambhra Nada¹, Charan Singh Rayat¹, Swapnil U. Rane¹, Vinay Sakhuja² and Kusum Joshi¹

1Department of Histopathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India and 2Department of Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India

Correspondence and offprint requests to: Kusum Joshi; E-mail: kus_joshi@yahoo.com

Abstract
Collagenofibrotic glomerulopathy (CG) is a rare cause of idiopathic nephrotic syndrome characterized by massive accumulation of atypical Type III collagen fibrils within the mesangial matrix and subendothelial space of the glomeruli. A definite diagnosis can be established when typical histological findings are supported by electron microscopy. This disease exhibits indolent progression and as yet has no specific treatment. The present article reviews the clinicopathological features, epidemiology and proposed mechanisms of pathogenesis of CG. A search of the English language literature identified 38 cases of CG, of which 22 are reported from Asian countries. An additional three cases are being reported from this Institute in India and are illustrated herein. These reports contribute to a better understanding of this disease, which although not as prevalent, should be considered as a differential diagnosis in cases of mesangiocapillary form of glomerular injury.

Keywords: banded collagen; collagenofibrotic glomerulopathy; nephrotic syndrome; Type III collagen

Introduction
Collagenofibrotic glomerulopathy (CG) is a rare condition characterized by deposition of Type III collagen fibers in the subendothelial space and mesangium of the glomerulus [1–9]. Fewer than 40 cases have been described in the literature under several names, including primary glomerular fibrosis, Collagen III glomerulopathy and CG [4]. The first report of this entity, in the late 70s from a team of Japanese doctors, considered this disease to be a variation of the nail–patella syndrome in the absence of skeletal abnormalities [10, 11]. Later reports clarified that this entity is a new type of hereditary glomerulopathy [12]. The pathological features are characteristic, although the clinical picture can be varied. The patients range in age from 2–66 years, with no sex predilection. The most common clinical presentation is proteinuria with or without associated nephrotic syndrome, with minor alterations in renal function [4, 5].

Materials and methods
We have identified three cases of CG that occurred over a period of 5 years (2006–2010) from among 5370 native and allograft renal biopsies from the archival material of the Department of Histopathology, Postgraduate Institute of Medical Education and Research, Chandigarh (India). The clinicopathological features of the three cases are summarized in Table 1. A literature search for CG was conducted using PubMed, limited to the English language, using keywords ‘CG’ and ‘Type III collagen glomerulopathy’. In this article, we have reviewed the pathogenesis, clinical and pathological features and the histological differential diagnosis of this disease and added three cases of this rare entity to the existing literature.

Discussion and review

Epidemiology
CG appears to be relatively common in Asian countries. Sixteen of 38 reported cases have occurred in patients of Japanese descent. The other reports are by Gubler et al. [12] from France (10 cases), Dombros and Katz [11] from Canada (1 case), Imbasciati et al. [2] from Italy (1 case), Vogt et al. [13] from the USA (1 case) and Ferreira et al. [14] from Brazil (3 cases). It is also interesting to note that 10 of 12 cases in the pediatric age group are from France [12]. There are nine cases from India [15–17], including the three cases of the present study, further confirming that this disease is relatively common in Asia.

Etiopathogenesis
Although the etiopathogenesis of this glomerulopathy remains unclear, it appears that ethnic/genetic factors play an important role. Clustering of the cases from Japan points to either environmental or ethnic factors in the cause of the disease while occurrence of the disease in siblings points to a genetic etiology [6]. There are two major theories regarding the origin of the accumulated spiraled and frayed collagen. One concept is that the abnormal Type III collagen is produced endogenously by the mesangium; alternatively, there is some evidence of extra-renal involvement with CG leading to a hypothesis that CG may be a systemic disease with...
abnormal metabolism of Type III collagen [8, 12, 18]. Although Type III collagen is not a normal constituent of the glomerular mesangium, in vitro studies have shown that mesangial cells contain messenger RNA for the interstitial collagen α1 (III), suggesting that a phenotypic alteration of mesangial cells can produce large amounts of Type III collagen [19]. Furthermore, mesangial cells in CG have been shown to undergo myoﬁbroblastic transformation (as evidenced by production of α smooth muscle actin and formation of sub-plasmalemmal ﬁlaments), which are postulated to be the source of Type III collagen [20].

Type III collagen is synthesized as a large precursor molecule, Type III pro-collagen, which then is converted to Type III collagen after enzymatic cleavage of its N-terminal peptide. Thus, increased serum levels of this N-terminal pro-collagen Type III peptide (PIIINP), found in patients with diseases presenting with ﬁbrosis, indicate excessive conversion of Type III pro-collagen into Type III molecule, Type III pro-collagen, which then is converted to Type III collagen after enzymatic cleavage of its N-terminal peptide. Thus, increased serum levels of this molecule, Type III pro-collagen, which then is converted to Type III collagen after enzymatic cleavage of its N-terminal peptide. Thus, increased serum levels of this molecule may reach the nephrotic range in patients with chronic kidney disease [20–22].

Clinical presentation

Analysis of the 41 reported cases (including the current series) shows that all age groups are affected and there is no sex predilection. The incidence of this entity is highest between the fourth and seventh decades; however, 13 cases in children up to the age of 15 years have been reported [12–14]. Notably, all 10 cases reported from France were in the pediatric age group [12]. Hence, this disease may be divided into two different clinical subtypes, an adult-onset type and a pediatric type. The most common presenting feature of CG is edema and/or persistent proteinuria that may reach the nephrotic range in –60% of patients (Table 2) [1–4, 7–9, 12, 14–17]. Hypertension is another early feature, which may be detected at the time of presentation (Table 2) [2, 6, 13–15, 17]. The natural history of CG is variable, but the disease is progressive, at least in a subset of patients. An occasional case has been associated with factor H deﬁciency [13]. Renal failure is described within 3 years of diagnosis in one patient [1]. In other patients, symptoms progress steadily with increasing renal insufﬁciency and eventual failure [4]. The disease appears to be primarily a renal process, barring an occasional case report of extrarenal involvement [4, 18]. The severity of the disease at presentation is highly variable, and its pace of progression is unpredictable.

Pathological features

Histopathologically, light microscopy shows lobular bland-appearing glomeruli due to global expansion of the mesangium with thickening of the peripheral capillary walls but no substantial mesangial hypercellularity (Figure 1a and b). The mesangial expansion is due to the accumulation of amorphous, weakly periodic acid Schiff (PAS)-positive material mimicking amyloid deposits. However, Congo red and thioflavine stains are completely negative. On Masson’s trichrome stain, the deposited material reveals blue staining (Figure 2d). The capillary lumina are narrowed but not occluded. The thickened capillary walls show focal reduplication; however, PAS and methenamine silver stains clearly highlight that the capillary basement membranes are normal and thickening of the wall is due to sub-endothelial deposition of pale amorphous material (Figure 1c). Usually, no endocapillary or extracapillary proliferation is seen in CG. In the advanced stage, capillary lumens are narrowed by the expanded mesangium and thickened capillary walls and glomeruli show a nodular appearance suggestive of diabetic nephropathy or monoclonal immunoglobulin deposition disease. However, unlike these two entities, the nodular lesions are weakly PAS positive or PAS negative in CG. Patchy tubular atrophy and interstitial ﬁbrosis may be present, and these changes are proportional to the degree of global glomerulosclerosis. Arteriolar hyalinosis and thickening of the walls of arteries can be seen, probably secondary to hypertension.

| Case no. | Age (years) | Clinical presentation | Histopathology | Direct immunofluorescence | Electron microscopy |
|----------|-------------|-----------------------|----------------|---------------------------|-------------------|
| 1.       | 53/male     | Known case of psoriasis with nephrotic syndrome (24-h urinary protein 5 g/day) hypertension (BP 180/90 mmHg), normal serum creatinine. | Mesangiocapillary pattern with capillary wall thickening and mesangial expansion by pale PAS-negative material. | Negative for all immunoglobulins except for segmental trapping for C3 in an occasional glomerulus. | Curvilinear collagen structures arranged in a disorganized manner in sub-endothelial and mesangial regions. The fibrils further demonstrated a specific banding pattern of 50–65 nm periodicity, thereby indicating banded Type III collagen. Lamina densa was unremarkable. |
| 2.       | 32/male     | Nephrotic syndrome (24-h urinary protein 3.6 g/day), normal serum creatinine. | Glomeruli showed lobular accentuation with narrowing of the capillary lumina by pale PAS-negative material. | Negative for all immunoglobulins and complement. | Banded collagen fibrils in the subendothelial and mesangial location; however, no fibrils are noted in the lamina densa. |
| 3.       | 40/male     | Nephrotic syndrome (24-h urinary protein 2.0 g/day, serum albumin 21 g/L; total cholesterol 9.2 mmol/L) | Glomeruli showed lobular accentuation due to deposition of homogeneous PAS and Congo red-negative deposits mainly in the expanded mesangium and sub-endothelial areas. An occasional glomerulus, in addition, revealed lesions of nodular glomerulosclerosis. | Negative for all immunoglobulins and complement. | Disorganized collagen fibrils with typical periodicity in mesangial and subendothelial location. No fibrils noted in the lamina densa. |
Staining for immunoglobulins and complement components is usually negative. Focal and segmental trapping for immunoglobulin M and complement C3 may be found in glomeruli, corresponding to the sub-endothelial hyaline deposits seen on light microscopy, which probably represent insudated plasma proteins and are not indicative of immune complex-mediated process. However, a single case of CG associated with immune complex deposits has been reported in the literature [7].

Electron microscopy is essential to establish a definitive diagnosis of CG and the pathological findings should be recognized with certainty. It is characterized by massive accumulations of banded collagen in glomerular mesangial and sub-endothelial zones. Abnormal accumulation of banded collagen

Table 2: Clinical profile of published cases of collagenofibrotic glomerulopathy in literature

| Reference year | Country of study | Age in years (no. of cases) | Sex (no. of cases) | Clinical presentation (no. of cases) | Blood pressure (mmHg) | Proteinuria (g/day) | Microscopic hematuria (no. of cases) | Creatinine (μmol/L) |
|----------------|------------------|----------------------------|-------------------|--------------------------------------|----------------------|-------------------|-------------------------------------|-------------------|
| Arakawa et al. [4]; 1979 | Japan | 32 F | Edema, proteinuria | 130/70 | 0.1–0.8 | + | 114.9 |
| Dombros and Katz [11]; 1982 | Canada | 34 F | Edema, proteinuria | NR | 0 | + | 53.0 |
| Kurosawa et al. [4]; 1984 | Japan | 64 M | Edema, proteinuria | 190/104 | 1.5–5.0 | + | 229.8 |
| Yoshida et al. [4]; 1985 | Japan | 36 M | Proteinuria | 170/100 | 4.9 | NR | 371.3 |
| Fukuta and Monden [4]; 1985 | Japan | 65 M | Proteinuria | 184/84 | 2.7 | NR | 141.4 |
| Sanaka et al. [4]; 1986 | Japan | 30 F | Proteinuria | 180/106 | 8.6 | + | 88.4 |
| Dombros and Katz [11]; 1982 | Canada | 34 F | Hematuria | NR | 0 | + | 203.3 |
| Kurosawa et al. [4]; 1984 | Japan | 64 M | Edema, proteinuria | 190/104 | 1.5–5.0 | + | 229.8 |
| Yasuda et al. [4]; 1984 | Japan | 42 F | Proteinuria | 180/92 | 0.5–1.3 | + | 79.6 |
| Isoda et al. [4]; 1985 | Japan | 36 M | Proteinuria | 170/100 | 4.9 | NR | 371.3 |
| Fukuta and Monden [4]; 1985 | Japan | 65 M | Proteinuria | 184/84 | 2.7 | NR | 141.4 |
| Sanaka et al. [4]; 1986 | Japan | 49 M | Proteinuria | 180/106 | 8.6 | + | 88.4 |
| Imbasciati et al. [2]; 1991 | Italy | 49 F | Hypertension, proteinuria | 180/110 | 0.8–1.2 | + | 79.6 |
| Gubler et al. [12]; 1993 | France | 1–15 (10) | M(7) F(3) | Proteinuria (4) Hematoproteinuria (6) | 180/92 | 0.8–1.2 | + | 79.6 |
| Yoshida et al. [3]; 1993 | Japan | 49 F | Proteinuria | 180/92 | 0.6 | – | 70.7 |
| Mizui et al. [4]; 1993 | Japan | 49 F | Proteinuria | 180/92 | 0.6 | – | 70.7 |
| Ozu et al. [4]; 1994 | Japan | 49 F | Proteinuria | 182/90 | 8.0 | – | 88.4 |
| Vogt et al. [13]; 1995 | USA | 2 M | Hypertension, heart failure | 166/28 | 0.6 | + | NR |
| Tamura et al. [6]; 1996 | Japan | 33 F | Facial edema, hypertension | 180/120 | 6.5 | – | 167.9 |
| Hisakawa et al. [7]; 1998 | Japan | 66 M | Edema, proteinuria | 160/90 | 2.5 | NR | 97.2 |
| Yoshida et al. [8]; 1999 | Japan | 38 M | Edema, proteinuria | 170/100 | 4.9 | + | 371.3 |
| Moriga et al. [9]; 2003 | Japan | 65 F | Anemia, hypertension, proteinuria | 140/70 | 3.6–6.3 | – | 88.4 |
| Suzuki et al. [4]; 2004 | Japan | 6 F | Proteinuria | 160/80 | 3.2 | + | 26.52 |
| Ferreira et al. [14]; 2009 | Brazil | 55 F(3) | Hypertension, hemotoproteinuria | NR | 1.18 | + | NR |
| Khubchandani et al. [15]; 2010 | India | 43 F(1) | Hypertension, hemotoproteinuria | NR | 1.6 | + | NR |
| 21 | Hypertension, hemotoproteinuria | NR | 2.49 | + | 108.7 |
| 15 | Hypertension, hematoproteinuria | Hypertension, proteinuria | 170/110 | 5.8 | – | NR |
| 20 | Hypertension, proteinuria | 150/100 | Nephrotic range | Albumin + | – | 176.8 |
| 20 | Hypertension, proteinuria | 180/100 | Proteinuria, hypertension, Psoriasis | 140/70 | 3.6 | – | 88.4 |
| Soni SS et al. [16]; 2011 | India | 26 M | Hodgkin lymphoma with proteinuria | NR | 1.6 | – | 114.9 |
| Patro KC et al. [17] | India | 43 F | Hypertension, hemotoproteinuria | 190/110 | 5.8 | + | 74.3 |
| 20 | Proteinuria, hypertension | 160/90 | 3.4 | – | 176.8 |
| Present series | India | 53 M | Proteinuria, hypertension, Psoriasis | 180/100 | 5.0 | – | 97.2 |
| 32 | Proteinuria | 140/70 | 3.6 | – | 88.4 |
| 40 | Proteinuria | 130/70 | 2.0 | – | 90.2 |

F, female; M, male; +, Positive; –, Negative; NR, not reported
collagen is also an ultra-structural hallmark of nail–patella syndrome glomerulopathy, in which the profiles of banded collagen occur predominantly within the lamina densa of the glomerular basement membranes. The two diseases can thus be distinguished by the location of Type III collagen (Figure 2a and b). At high magnification, the fibrils are arranged in irregular bundles, show a distinct periodicity of 43–65 nm and appear curved, frayed, and worm and comma shaped when sectioned transversely (Figure 2c and d). Because of the abnormal shape, size and organization of the bundles of Type III collagen fibrils, these appear 'atypical' or abnormal and can be clearly differentiated from the fibrils of regular Type III collagen (which are arranged in straight lines) and from other types of organized glomerular deposits, e.g. the deposits of amyloid, fibrillary glomerulonephritis and immunotactoid glomerulopathy [23]. Although the banded morphology of collagen fibrils can be identified with routine staining for electron microscopy, it is better visualized by special staining with tannic acid lead or phosphotungstic acid. Discrete electron-dense immune complex-type deposits usually are not present, although subendothelial dense deposits can be seen infrequently. A variable degree of epithelial foot process effacement is usually seen [23].

Collagen III immunohistochemistry shows focal, segmental or diffuse and generalized mesangial staining, primarily depending on the stage of the disease process. Immunostaining for other fibrillar collagen types typically is negative and Type IV collagen is normal. However, in an occasional case, both Types III and I or III and V collagens could be detected [3, 4, 9].

Histological differential diagnosis

CG at the light microscopy level has enlarged lobular glomeruli, with the membranoproliferative/mesangiocapillary pattern. Thus, it has to be differentiated from (i) membranoproliferative glomerulonephritis, (ii) diabetes, (iii) amyloidosis and other fibrillary glomerulopathies and (iv) monoclonal immunoglobulin deposition disease [4, 19]. Although the confirmation of a diagnosis of CG has to be obtained by electron microscopy or specific immunohistochemistry, clues to its diagnosis can be obtained at light microscopy level. The tram track appearance, mesangial cellularity and typical immunofluorescence pattern of MPGN are not seen in these cases. The sub-endothelial and mesangial collagen deposits lack the strong PAS positivity, which is consistently seen in diabetes and light-chain deposition disease. Congo red stain and Thioflavin T (for amyloid) are negative. Masson’s trichrome stain is useful as it identifies the blue-colored collagen within the capillary loops and mesangium.

Treatment and prognosis

No specific treatment is available for this entity. Supportive measures for control of hypertension and edema may help
to relieve the symptoms. Dialysis/renal transplantation may be required for patients with end-stage renal disease. Although very few patients have received a transplant, to date none have shown recurrence of the disease [4]. It is well documented in dermatological conditions that the use of systemic glucocorticoids can diminish the deposition of interstitial collagens [24]. However, their role in CG is doubtful and a future clinical trial on the regular use of steroids is unlikely because of the rarity of the disease.

Conflict of interest statement. None declared.

References

1. Ikeda K, Yokoyama H, Tomosugi N et al. Primary glomerular fibrosis: A new nephropathy caused by diffuse intra-glomerular increase in atypical type III collagen fibres. Clin Nephrol 1990; 33: 155–159
2. Imbasciati E, Gherardi G, Morozumi K et al. Collagen type III glomerulopathy: a new idiopathic glomerular disease. Am J Nephrol 1991; 11: 422–429
3. Yoshida F, Yuzawa Y, Shigematsu H et al. Nephrotic syndrome with massive accumulation of type I and type III collagen in the glomeruli. Intern Med 1993; 32: 171–176
4. Alchi B, Nishi S, Narita I et al. Collagenofibrotic glomerulopathy: clinicopathologic overview of a rare glomerular disease. Am J Kidney Dis 2002; 39: 499–506
5. Iskandar SS, Herrera GA. Glomerulopathies with organized deposits. Semin Diag Pathol 2002; 19: 116–132
6. Tamura H, Matsuda A, Kidogushi M et al. A family with two sisters with Collagenofibrotic Glomerulonephropathy. Am J Kidney Dis 1996; 27: 588–595
7. Hisakawa N, Yasuoka N, Nishiya K et al. Collagenofibrotic glomerulonephropathy associated with immune complex deposits. Am J Nephrol 1998; 18: 134–141
8. Yasuda T, Imai H, Nakamoto Y et al. Collagenofibrotic glomerulopathy: a systemic disease. Am J Kidney Dis 1999; 33: 123–127
9. Morita H, Hasegawa T, Minamoto T et al. Collagenofibrotic glomerulopathy with a widespread expression of type-V collagen. Virchows Arch 2003; 442: 163–168
10. Vernier RL, Hoyer JR, Michael AF. The nail-patella syndrome—pathogenesis of the kidney lesion. Birth Defects Orig Artic Ser 1974; 10: 57–59
11. Dombros N, Katz A. Nail-patella like renal lesion in the absence of skeletal abnormalities. Am J Kidney Dis 1982; 1: 237–240
12. Gubler MC, Dommergues JP, Foulard M et al. Collagen type III glomerulopathy: a new type of hereditary nephropathy. Pediatr Nephrol 1993; 7: 354–360

Fig. 2. Electron microscopic features of collagenofibrotic glomerulopathy. (a) Expanded subendothelial and mesangial space by deposition of fibrillar material. The overlying podocytes show foot process effacement (uranyl acetate and lead citrate; original magnification ×10 000); (b) the collagen deposits are noted in the sub-endothelial location and have a disorganized appearance. The glomerular basement membrane (indicated by arrow) itself shows no collagen fibrils (uranyl acetate and lead citrate; original magnification ×17 000); (c) collagen fibrils have typical curvilinear and disorganized morphology when transversely cut indicative of atypical Type III collagen (uranyl acetate and lead citrate; original magnification ×21 500); (d) on high magnification, the organized deposits have banded appearance (indicated by arrow) with typical periodicity of 60 nm, indicative of fibrillar Type III collagen (uranyl acetate and lead citrate; original magnification ×28 000).
13. Vogt BA, Wyatt RJ, Burke BA et al. Inherited factor H deficiency and collagen type III glomerulopathy. Pediatr Nephrol 1995; 9: 11–15
14. Ferreira R D R, Custódio FB, Guimarães C et al. Collagenofibrotic glomerulopathy: three case reports in Brazil. Diagn Pathol 2009; 4: 33
15. Khubchandani SR, Chitale AR, Gowrishankar S. Banded collagen in the kidney with special reference to collagenofibrotic glomerulopathy. Ultrastruct Pathol 2010; 34: 68–72
16. Soni SS, Gowrishankar S, Nagarik AP et al. Collagenofibrotic glomerulopathy in association with hodgkin’s lymphoma. Saudi J Kidney Dis Transpl 2011; 22: 126–129
17. Patra KC, Jha R, Sahay M et al. Collagenofibrotic glomerulopathy-case report with review of literature. Indian J Nephrol 2011; 21: 52–55
18. Mizuiri S, Hasegawa A, Kikuchi A et al. A case of collagenofibrotic glomerulopathy associated with hepatic perisinusoidal fibrosis. Nephron 1993; 63: 183–187
19. Scheinman JI, Tanaka H, Haralson H et al. Specialized collagen mRNA and secreted collagens in human glomerular epithelial, mesangial and tubular cells. J Am Soc Nephrol 1992; 2: 1475–1483
20. Naruse K, Ito H, Moriki T et al. Mesangial cell activation in the collagenofibrotic glomerulopathy. Case report and review of the literature. Virchow Arch 1998; 433: 183–188
21. Soylemezoglu O, Wild G, Dalley AJ et al. Urinary and serum type III collagen: markers of renal fibrosis. Nephrol Dial Transplant 1997; 12: 1883–1889
22. Keller F, Rehbein C, Schwarz A et al. Increased procollagen III production in patients with kidney disease. Nephron 1988; 50: 332–337
23. Herrera GA, Turbat-Herrera EA. Renal diseases with organized deposits: An algorithmic approach to classification and clinicopathologic diagnosis. Arch Pathol Lab Med 2010; 134: 512–531
24. Autio P, Oikarinen A, Melkko J et al. Systemic glucorticoids decrease the synthesis of type I and type III collagen in human skin in vivo, whereas isotretinoin treatment has little effect. Br J Dermatol 1994; 131: 660–663

Received for publication: 19.5.11; Accepted in revised form: 7.9.11